Few moments in brain tumor care feel worse than a follow-up MRI that shows a bright new spot after treatment. Doctors cannot always tell from that scan alone whether the spot is glioblastoma recurrence or damage left by radiation and chemotherapy. Families can spend weeks waiting for the next scan to find out. A PET tracer approved by the FDA in September 2026 gives doctors another way to look at that spot. The new scan may also spare some patients a repeat brain biopsy.
Why Glioblastoma Recurrence Is Hard to Confirm on an MRI
Contrast MRI is the standard scan for checking a glioma after treatment. A dye travels through the blood and leaks into spots where the brain’s normal barrier has broken down. Growing tumor breaks that barrier. Tissue injured by radiation or chemotherapy can break the barrier too, so both can light up the same way on screen.
Doctors use two terms for the look-alike damage. Pseudoprogression is swelling and leaky blood vessels that show up in the weeks or months after radiation. That swelling usually settles down without new treatment. Radiation necrosis is dead tissue that can appear months to years later and may need care of its own.
A care team reads an unclear scan alongside other clues. Doctors check how long it has been since radiation. They also look at whether the bright area sits inside the zone that got the highest dose. New symptoms, such as weakness, speech trouble, or seizures, count as a clue too.
Why a Biopsy Is Not Always the Answer
In some other cancers, a doctor can settle a confusing scan with a needle biopsy or a blood test. Taking repeated samples from the brain is far harder, since each procedure brings surgical risk and reaches only one small area. Without a safe test, the usual plan is to wait a month or two and scan again.
Weeks of waiting are hard on everyone. A written list of questions is part of turning fear into a plan before the next visit. The same list helps if a second doctor reviews the images.
How a New PET Scan Checks for Glioblastoma Recurrence
Doctors call the new tracer 18F-FET. The FDA decision covers glioma brain tumors as a group, including glioblastoma. This tracer acts like an amino acid, one of the building blocks cells use to make protein. Glioma cells pull in amino acids faster than healthy brain tissue and faster than many treatment changes. As a result, active tumor usually shows up brighter on the PET scan.
For someone facing possible glioblastoma recurrence, the visit works much like other PET tests. A small dose of the tracer goes into a vein, and the scanner records where it builds up in the brain. Doctors then read the PET images next to the MRI. A spot that looks bright on MRI but takes up little tracer points toward treatment damage.
PET detail of this kind may help doctors judge whether treatment is working and spot tumor that has come back. That use grew out of a multi-year trial at UC San Francisco, whose data supported the FDA decision. Access may grow slowly at first, since the tracer’s radioactive fluorine is short-lived and a lab has to make it near the scanner.
Until now, American doctors mostly leaned on other tools, such as perfusion MRI, which tracks blood flow. Another option, MR spectroscopy, reads chemical signals in tissue. Those tests help, but their results can still come back unclear.
How Common False Alarms Are After Radiation
False alarms are common enough that doctors plan around them. A 2023 study of 284 people with glioblastoma, published in Neuro-Oncology Practice, found pseudoprogression in about 19% of patients three months after radiation. By six months, the rate had dropped to 7%.
Either kind of wrong call can hurt the patient. If doctors read harmless swelling as tumor, a patient may stop a treatment that was working. If they read real tumor as swelling, a patient may stay on a treatment that has stopped helping.
Some details make a false alarm more likely. Researchers in that study tied pseudoprogression to a tumor gene marker called MGMT methylation and to the absence of new neurological symptoms. A person whose MGMT status is already known can ask the care team how much that marker changes the odds for their own scan.
Switching treatment too early did not appear to help either. For patients later confirmed to have tumor growth at three months, an early change of treatment brought no survival gain. The study authors advised continuing chemotherapy when an MRI result is unclear.
What Better Imaging Changes When Glioblastoma Recurrence Is Suspected
When the PET scan points to active tumor, the team can talk sooner about surgery, a new drug, or focused radiation aimed at the new growth. If the scan points to treatment damage instead, the person may be able to stay on a plan that is working. That second result can also spare someone a risky operation on tissue that may settle on its own.
For a neurosurgeon, the PET map can help plan a second operation. Knowing which parts of a bright area contain active tumor can guide how much tissue a surgeon removes. Imaging is still one piece of a brain tumor treatment plan that also weighs the person’s symptoms, age, and goals. Two people with the same scan result may choose different paths for those reasons.
Families can add a piece of evidence of their own. A short daily note of headaches, weakness, speech changes, or seizures gives the team something to compare against each scan. Even a log with nothing new in it can help, since false alarms came more frequently in people without new symptoms.
Common Questions About Glioblastoma Recurrence and PET Scans
Does the new PET scan replace MRI?
No. MRI is still the main scan for follow-up care. A PET scan adds a second layer of detail when an MRI change is hard to read. A person can ask whether their next unclear MRI would qualify for a PET follow-up.
Is the tracer safe?
PET tracers give only a small radiation dose, and that dose fades within hours because the radioactive fluorine breaks down quickly. Many centers ask patients to fast for a few hours before the scan. Confirming the prep instructions a day ahead saves a wasted trip.
Will insurance cover the scan?
Coverage for a newly approved scan can lag behind the FDA decision itself. Before scheduling, the person can ask the imaging center three things: whether it offers the scan yet, whether the plan needs prior approval, and what the out-of-pocket cost may be. If the center does not offer the scan yet, the care team may know the nearest hospital that does.
What to Ask After a Confusing Follow-Up MRI
A bright spot on a post-treatment MRI does not settle the question of glioblastoma recurrence by itself. With an FDA-approved tracer now available, a person can ask whether the change could be treatment damage. The next question is whether a PET scan would help sort out that change before the treatment plan changes. Bringing the dates of radiation and chemotherapy to that visit helps the team judge timing, since false alarms show up most in the first months after treatment.
Sources
UC San Francisco. FDA Approves PET Imaging Agent for Brain Cancer Based on UCSF Data.
National Library of Medicine. Incidence and outcome of pseudoprogression after radiation therapy in glioblastoma patients: A cohort study.
